Biomarin Pharmaceutical Q2 2024 Adj EPS $0.96 Beats $0.35 Estimate, Sales $712.03M Beat $662.05M Estimate
Portfolio Pulse from Benzinga Newsdesk
Biomarin Pharmaceutical (NASDAQ:BMRN) reported Q2 2024 earnings of $0.96 per share, significantly beating the analyst estimate of $0.35. The company also reported sales of $712.03 million, surpassing the $662.05 million estimate and marking a 19.61% increase from the same period last year.
August 05, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biomarin Pharmaceutical reported Q2 2024 earnings of $0.96 per share, beating the analyst estimate of $0.35 by 174.29%. The company also reported sales of $712.03 million, surpassing the $662.05 million estimate and marking a 19.61% increase from the same period last year.
The significant beat on both EPS and sales estimates, along with a strong year-over-year sales growth, is likely to positively impact Biomarin's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100